Mia sells MNK 59.8: It is well above one times, making it relatively less risky among the master limited partnerships.

It provides many of its services on the basis of long-term, fixed-fee contracts, insulating against some of the wilder swings of the commodities that it trades in. Despite the energy slump, Enterprise Products Partners L.P. (NYSE: EPD) once again just raised its distribution 1%. The company maintains a very good long-term position in the market. We screened the Jefferies list for the stocks with the biggest upside to the posted price targets. The Jefferies team had truly found some noteworthy companies to buy, and some are Wall Street favorites that for one reason or another were sold off, or have fallen out of favor. A new research report from Jefferies highlights value stocks to buy this week.


Johnna:
However, given the alternatives, investors are likely to stay in, and they seem to buy every significant dip.

Tiny:
Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Acquisition Of Therakos, Inc.

Danette:
Therakos therapeutic platforms, including the latest generation Therakos CELLEX Photopheresis System, are the world's only approved, fully integrated systems for administering autologous immune cell therapy through ECP.

Lizeth:
Therakos Photopheresis is approved by the U.S.

Candy:
Completion of the transaction is subject to regulatory approvals and other customary conditions.

Rikki:
With roughly 60 percent of Therakos' revenue in the U.S., we expect fiscal 2015 net sales of $185 to $195 million, and anticipate high single-digit growth off that base going forward, driven primarily by the U.S.

Robena:
Assuming a close in late fiscal 2015, the transaction is expected to be accretive by no less than $0.10 per share to Mallinckrodt's adjusted diluted fiscal 2016 earnings and increasingly accretive thereafter.

Dona:
The company expects to augment sales of Therakos products with its skilled customer experience teams, which include sales, marketing, training and clinician support.

Clarita:
The Therakos commercial team will be integrated into Mallinckrodt's current critical care organization within its Hospital Specialty Brands business.

April:
Installed in more than 350 academic medical centers and hospitals around the world, it is delivered in hospital-based out-patient clinics via an innovative, fully integrated, drug-device combination that is widely reimbursed globally.

Mallinckrodt Plc Ordinary Share (NYSE:MNK)
//stockhand.net/us/?q=nyse%3Amnk&id=292284